Researches and develops allergy treatments. Sells injectable allergen-specific immunotherapies. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (-3% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 7.4× for every dollar of annual revenue.
No analyst target is on record for this company.
An investor who bought at the very peak is down 72% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $102.2M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $74.5M against $102.2M in annual sales.
The stock sits at $0.15. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.